Table 1.
Study | Diagnostic group | Number | Gender (M/F) | Age (years) | MMSE score | APOE ε4 (heterozygote/homozygote) | Hippocampal volume (cm3) | Entorhinal cortex volume (cm3) |
---|---|---|---|---|---|---|---|---|
ADNI1 | NC | 124 | 62/62 | 74 [60–90] | 29 [25–30] | 26/2 | 3.7 ± 0.4 | 1.9 ± 0.3 |
AD | 124 | 65/59 | 75 [55–90] | 23 [20–27] | 59/25 | 2.8 ± 0.5 | 1.4 ± 0.3 | |
MCI | ||||||||
sMCI-2y | 134 | 85/49 | 75 [55–88] | 28 [24–30] | 53/12 | 3.3 ± 0.5 | 1.7 ± 0.4 | |
pMCI-2y | 89 | 51/38 | 75 [56–88] | 26 [23−30] | 49/15 | 2.9 ± 0.5 | 1.5 ± 0.4 | |
sMCI-5y | 47 | 33/14 | 75 [60–86] | 28 [24–30] | 17/0 | 3.5 ± 0.4 | 1.9 ± 0.3 | |
pMCI-5y | 126 | 72/54 | 74 [55–88] | 27 [23–30] | 67/22 | 3.0 ± 0.5 | 1.5 ± 0.4 | |
ADNIGO/2 | NC | 106 | 50/56 | 72 [56–85] | 30 [24–30] | 28/2 | 3.8 ± 0.5 | 1.9 ± 0.3 |
AD | 106 | 57/49 | 75 [56–90] | 23 [19–26] | 45/24 | 3.0 ± 0.5 | 1.5 ± 0.3 | |
MCI | ||||||||
sMCI-2y | 64 | 34/30 | 71[55–85] | 28 [24–30] | 18/7 | 3.6 ± 0.5 | 1.8 ± 0.3 | |
pMCI-2y | 44 | 24/20 | 73 [57–85] | 26 [24–30] | 23/9 | 3.0 ± 0.5 | 1.6 ± 0.4 | |
sMCI-5y | 24 | 13/11 | 68 [55–85] | 29 [25–30] | 7/3 | 3.8 ± 0.5 | 1.9 ± 0.3 | |
pMCI-5y | 51 | 28/23 | 73 [57–85] | 27 [24–30] | 25/10 | 3.1 ± 0.5 | 1.6 ± 0.3 |